Browse ERMN

Summary
SymbolERMN
Nameermin, ERM-like protein
Aliases JN; ERMIN; juxtanodin; KIAA1189
Chromosomal Location2q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton
Domain -
Function

Plays a role in cytoskeletal rearrangements during the late wrapping and/or compaction phases of myelinogenesis as well as in maintenance and stability of myelin sheath in the adult. May play an important role in late-stage oligodendroglia maturation, myelin/Ranvier node formation during CNS development, and in the maintenance and plasticity of related structures in the mature CNS (By similarity).

> Gene Ontology
 
Biological Process GO:0001763 morphogenesis of a branching structure
GO:0007015 actin filament organization
GO:0008360 regulation of cell shape
GO:0022604 regulation of cell morphogenesis
Molecular Function GO:0003779 actin binding
GO:0051015 actin filament binding
Cellular Component GO:0005938 cell cortex
GO:0030175 filopodium
GO:0030424 axon
GO:0033267 axon part
GO:0033269 internode region of axon
GO:0033270 paranode region of axon
GO:0043025 neuronal cell body
GO:0043209 myelin sheath
GO:0044297 cell body
GO:0044304 main axon
GO:0098858 actin-based cell projection
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolERMN
Nameermin, ERM-like protein
Aliases JN; ERMIN; juxtanodin; KIAA1189
Chromosomal Location2q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ERMN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolERMN
Nameermin, ERM-like protein
Aliases JN; ERMIN; juxtanodin; KIAA1189
Chromosomal Location2q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ERMN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolERMN
Nameermin, ERM-like protein
Aliases JN; ERMIN; juxtanodin; KIAA1189
Chromosomal Location2q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ERMN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.030.884
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3840.397
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2290.531
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.2180.0476
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1130.271
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.3430.269
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.7890.249
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1150.286
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.370.732
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2930.529
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1110.857
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3560.107
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ERMN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolERMN
Nameermin, ERM-like protein
Aliases JN; ERMIN; juxtanodin; KIAA1189
Chromosomal Location2q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ERMN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolERMN
Nameermin, ERM-like protein
Aliases JN; ERMIN; juxtanodin; KIAA1189
Chromosomal Location2q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ERMN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ERMN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolERMN
Nameermin, ERM-like protein
Aliases JN; ERMIN; juxtanodin; KIAA1189
Chromosomal Location2q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ERMN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolERMN
Nameermin, ERM-like protein
Aliases JN; ERMIN; juxtanodin; KIAA1189
Chromosomal Location2q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ERMN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolERMN
Nameermin, ERM-like protein
Aliases JN; ERMIN; juxtanodin; KIAA1189
Chromosomal Location2q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ERMN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolERMN
Nameermin, ERM-like protein
Aliases JN; ERMIN; juxtanodin; KIAA1189
Chromosomal Location2q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ERMN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.